Sequential Chemotherapy Using Gemcitabine, Nab-Paclitaxel, and mFOLFIRINOX for Treating Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

What this Trial Is About

This trial studies people with borderline resectable or locally advanced pancreatic adenocarcinoma, a type of pancreatic cancer. It evaluates the effects of a sequence of chemotherapy treatments using Gemcitabine - Abraxane nab-Paclitaxel followed by mFOLFIRINOX. These treatments are approved individually but not as a sequence, and this study aims to see how well this approach improves the ability to completely remove the tumor by surgery and other outcomes. Participants receive outpatient chemotherapy beginning with Gemcitabine and nab-Paclitaxel for one month, followed by mFOLFIRINOX for another month. Treatment cycles follow specific schedules with weekly or biweekly dosing depending on the drug. Imaging scans such as CT or MRI are performed every 8 weeks to monitor the disease and determine if the treatment should continue. After four months, patients may proceed to surgery, radiation, or further chemotherapy based on clinical decisions. During the study, participants are closely monitored with assessments including blood tests and imaging to evaluate tumor response, safety, and survival. Researchers track the rate of complete tumor removal R0 resection, progression-free survival, overall survival, adverse events, and disease control up to one year after treatment. The total study duration includes treatment and follow-up periods, ensuring detailed observation of patient outcomes and treatment tolerability.

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma